Man Group plc cut its position in shares of Teladoc Health Inc (NYSE:TDOC) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,647 shares of the health services provider’s stock after selling 376 shares during the period. Man Group plc owned 0.09% of Teladoc Health worth $4,649,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. CNB Bank lifted its stake in Teladoc Health by 100.0% in the third quarter. CNB Bank now owns 400 shares of the health services provider’s stock valued at $27,000 after acquiring an additional 200 shares during the last quarter. Capital Investment Advisory Services LLC increased its stake in shares of Teladoc Health by 800.0% during the 3rd quarter. Capital Investment Advisory Services LLC now owns 450 shares of the health services provider’s stock worth $30,000 after purchasing an additional 400 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Teladoc Health during the 1st quarter valued at $35,000. Tradewinds Capital Management LLC lifted its stake in shares of Teladoc Health by 186.0% in the 2nd quarter. Tradewinds Capital Management LLC now owns 615 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 400 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Teladoc Health by 32.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 621 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 152 shares during the last quarter.
In other Teladoc Health news, insider Adam C. Vandervoort sold 3,525 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $79.12, for a total value of $278,898.00. Following the completion of the sale, the insider now directly owns 1,114 shares of the company’s stock, valued at approximately $88,139.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lewis Levy sold 2,025 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $80.50, for a total transaction of $163,012.50. Following the completion of the sale, the insider now owns 5,655 shares in the company, valued at $455,227.50. The disclosure for this sale can be found here. Insiders sold a total of 68,774 shares of company stock worth $5,167,227 in the last ninety days. Insiders own 3.95% of the company’s stock.
TDOC stock opened at $80.03 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 6.55 and a quick ratio of 6.55. Teladoc Health Inc has a 52-week low of $42.08 and a 52-week high of $86.30. The company has a 50-day moving average of $77.48 and a two-hundred day moving average of $67.56. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of -55.58 and a beta of 1.40.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The company had revenue of $137.96 million for the quarter, compared to the consensus estimate of $136.46 million. During the same period last year, the business posted ($0.34) earnings per share. The firm’s revenue was up 24.3% compared to the same quarter last year. Equities analysts expect that Teladoc Health Inc will post -1.55 EPS for the current fiscal year.
TDOC has been the topic of several analyst reports. Jefferies Financial Group downgraded shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $80.00 target price on the stock. in a research report on Friday. Stifel Nicolaus assumed coverage on Teladoc Health in a research report on Monday, November 25th. They issued a “hold” rating and a $83.00 price target for the company. JPMorgan Chase & Co. upped their price target on Teladoc Health from $82.00 to $83.00 and gave the stock an “overweight” rating in a research note on Thursday, September 19th. Oppenheimer set a $83.00 price objective on Teladoc Health and gave the company a “buy” rating in a report on Friday, September 6th. Finally, Deutsche Bank started coverage on Teladoc Health in a research note on Thursday, September 12th. They issued a “buy” rating and a $76.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Teladoc Health has a consensus rating of “Buy” and a consensus price target of $80.73.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Further Reading: Why are gap-down stocks important?
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.